Creating stable antibody replacements on demand
Official title: Technology to Create Spiegel ERAbodies on Demand: Biostable Universal Antibody Replacements
Funded at Foundation for Applied Molecular Evolutn · NIH-10707168 · Data updated 2026-11-12
This study is exploring a new kind of antibody replacement called Spiegel ERAbodies, which can be made quickly and easily to help scientists better understand diseases and improve treatments, making the process faster and more affordable.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Foundation for Applied Molecular Evolutn NIH-funded |
| Lab location | 1 site (Alachua, United States) |
| Project start | September 20, 2022 |
| Project end | August 31, 2025 |
| Funding year | 2023 |
| Award (this year) | $193,125 |
| NIH project number | 5R21GM147764-02 |
| Project ID | NIH-10707168 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals involved in biomedical research or clinical diagnostics who require stable and effective binding agents for their studies.
✕Less likely to help
Patients who are not engaged in research or clinical diagnostics may not benefit directly from this technology.
What this research studies
This research focuses on developing a new type of antibody replacement called Spiegel ERAbodies, which can be created on demand for use in various biomedical applications. The approach utilizes an innovative platform that incorporates an expanded RNA alphabet, allowing for greater binding potential and stability compared to traditional antibodies. By enhancing the structural diversity and folding capabilities of these replacements, the researchers aim to provide a more reliable and efficient tool for scientists studying biological processes. This could significantly reduce the time and cost associated with producing antibodies.
Why it matters
Potential benefit: If successful, this research could lead to more accessible and reliable tools for diagnosing and treating diseases.
How similar studies have gone: While the concept of antibody replacements has been explored, the specific approach using an expanded RNA alphabet is novel and has not been extensively tested.
Where this research is happening
-
Foundation for Applied Molecular Evolutn
Alachua, United States Active
Researchers
- Principal investigator: Biondi, Elisa — Foundation for Applied Molecular Evolutn
- Study coordinator: Biondi, Elisa
Related research
Other NIH-funded projects on the same topics.
-
Tau and p-Tau blood biomarkers to predict outcomes after complicated mild traumatic brain injury
A research team is validating Tau and phosphorylated Tau as blood biomarkers to help predict which patients with complicated mild TBI will have poorer outcomes.
-
Custom molecules that destroy cancer proteins
Researchers are building synthetic molecules that stick to and cut cancer-related proteins to speed up cancer research and future treatments.
-
Creating molecules that can target and destroy cancer proteins
This study is working on new tools that can help target and break down proteins related to cancer, with the goal of making cancer treatments faster and more affordable for patients like you.
-
Improving COVID-19 diagnostics in low-resource settings
This study is looking at how DNA and RNA work together to make better tests for COVID-19 and other germs, so that patients can get quicker and more accurate results, especially in places that might not have a lot of resources.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.